TCL6148
TCL6148 is a ferroptosis inducer targeting GOT1, with a KD of 25.84 μM for GOT1. TCL6148 inhibits the viability of renal cell carcinoma 786-O and A498 cells, with IC50 values of 7.896 μM and 7.468 μM, respectively. TCL6148 induces ferroptosis by increasing Fe2+, ROS and lipid peroxidation, reducing GSH and inhibiting the GOT1/GPX4 pathway; it also inhibits proliferation and migration of RCC cells, enhances cellular sensitivity to Sunitinib (HY-10255A) and suppresses the growth of RCC xenograft tumors. TCL6148 can be used in research on renal cell carcinoma and ferroptosis.
For research use only. We do not sell to patients.
- Formula: C113H168N26O27S2
- Molecular Weight:2386.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
GOT1 25.84 μM (Kd) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 786-0 | IC50 |
7.896 μM
|
TCL6148 inhibits 786-O cell viability after 24 h exposure.
TCL6148 inhibits 786-O cell viability after 24 h exposure.
|
40379184 |
| A498 | IC50 |
7.468 μM
|
TCL6148 inhibits A498 cell viability after 24 h exposure.
TCL6148 inhibits A498 cell viability after 24 h exposure.
|
40379184 |
| HK-2 | IC50 |
210.5 μM
|
TCL6148 shows markedly lower cytotoxicity toward normal human renal tubular epithelial HK-2 cells.
TCL6148 shows markedly lower cytotoxicity toward normal human renal tubular epithelial HK-2 cells.
|
40379184 |
In Vitro
TCL6148 (0.78-50 μM) binds to purified GOT1 protein, with a Kd value of 25.84 μM[1].
TCL6148 (10 μM; 24 h) significantly suppresses GOT enzymatic activity in 786-O and A498 renal cell carcinoma (RCC) cells[1].
TCL6148 (0-50 μM; 24 h) potently inhibits the viability of 786-O (IC50 = 7.896 μM) and A498 (IC50 = 7.468 μM) renal cell carcinoma cells in a dose-dependent manner, while it shows extremely low cytotoxicity against normal HK-2 renal cells after 24 h of treatment (IC50 = 210.5 μM)[1].
TCL6148 (2-10 μM; 24 h) inhibits the migration of 786-O and A498 renal cell carcinoma (RCC) cells in a dose-dependent manner, exhibiting significant inhibitory effects after treatment with 10 μM for 24 h[1].
TCL6148 (2-10 μM; 24 h) inhibits the proliferation of 786-O and A498 renal cell carcinoma (RCC) cells in a dose-dependent manner, and the proportion of EdU-positive cells decreases by approximately 40% after treatment with 10 μM for 24 h[1].
TCL6148 (2 μM; 24 h) enhances the sensitivity of 786-O and A498 cells to Sunitinib, reducing the IC50 values of Sunitinib from 9.216 μM and 11.12 μM to 4.049 μM and 4.414 μM, respectively, and further inhibits cell migration and proliferation[1].
TCL6148 (2-10 μM; 24 h) induces ferroptosis in 786-O and A498 renal cell carcinoma cells in a dose-dependent manner by increasing intracellular Fe2+ accumulation, ROS production and lipid peroxidation, while decreasing GSH levels after 24 h of treatment[1].
Treatment with TCL6148 (2-10 μM; 24 h) downregulates the protein expression levels of GOT1 and GPX4 in a dose-dependent manner in 786-O and A498 renal cell carcinoma (RCC) cells[1].
TCL6148 (2 μM) enhances Sunitinib-induced ferroptosis in RCC cells, increasing the relative Fe2+ levels from 1.93 to 2.79 in 786-O cells and from 1.72 to 2.25 in A498 cells. Meanwhile, it further elevates ROS and MDA levels, reduces GSH levels, and further downregulates GOT1 and GPX4[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human RCC cell lines 786-O, A498, and normal human renal tubular epithelial cells HK-2
-
Concentration:0-50 μM
-
Incubation Time:24 h
-
Result:Reduced RCC cell viability in a dose-dependent manner, with IC50 values of 7.896 μM for 786-O, 7.468 μM for A498, and 210.5 μM for HK-2 cells.
Maintained HK-2 cell viability at 93.64% at 10 μM.
-
Cell Line:human RCC cell lines 786-O and A498
-
Concentration:2-10 μM
-
Incubation Time:24 h
-
Result:Suppressed RCC cell migration in a dose-dependent manner.
Decreased the relative migration rate of both cell lines to <20% compared to untreated controls at 10 μM.
-
Cell Line:human RCC cell lines 786-O and A498
-
Concentration:2-10 μM
-
Incubation Time:24 h
-
Result:Reduced the proportion of EdU-positive cells in a dose-dependent manner.
Decreased the percentage of EdU-positive cells by approximately 40% compared to untreated controls at 10 μM.
-
Cell Line:human RCC cell lines 786-O and A498
-
Concentration:2-10 μM
-
Incubation Time:24 h
-
Result:Downregulated protein expression levels of both GOT1 and GPX4 in a dose-dependent manner, with the most significant reduction observed at 10 μM.
-
Cell Line:human RCC cell lines 786-O and A498
-
Concentration:2 μM (TCL6148; combined with sunitinib at concentrations to determine IC50)
-
Incubation Time:24 h
-
Result:Reduced the IC50 of sunitinib from 9.216 μM to 4.049 μM in 786-O cells, and from 11.12 μM to 4.414 μM in A498 cells, indicating enhanced sunitinib sensitivity.
In Vivo
TCL6148 (15 mg/kg; once every 3 days; for 30 days) reduces the expression of GOT1 and GPX4 in 786-O xenograft tumor tissues, and the downregulation of GOT1 and GPX4 is more pronounced when TCL6148 is combined with Sunitinib (20 mg/kg)[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:15 mg/kg; 15 mg/kg (in combination with 20 mg/kg sunitinib)
-
Administration:s.c.; every three days; 30 days
-
Result:Significantly reduced tumor volume compared to the control group.
Showed good tolerance, with no significant changes in body weight observed throughout the experiment.
Decreased expression levels of GOT1 and GPX4 in tumor tissues.
Further suppressed tumor growth when combined with sunitinib compared to either treatment alone.
Caused a more pronounced reduction in GOT1 and GPX4 expression when combined with sunitinib compared to either treatment alone.
Chemical Information
-
Molecular Weight 2386.83
-
Formula C113H168N26O27S2
-
Sequence
Met-Cys-Leu-Ser-Phe-Arg-Phe-Ser-Phe-Glu-Leu-Ala-Val-Thr-Pro-Leu-Gln-Phe-Leu-His
-
Sequence Shortening
MCLSFRFSFELAVTPLQFLH
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)